Aaron is an Assistant Professor of Medical at Harvard Medical School and an Assistant Physician of Medicine at Massachusetts General Hospital. He is an accomplished scientist whose work focuses on advancing targeted therapies to benefit patients with lung cancer. His lab focuses on understanding the biological underpinnings of sensitivity and resistance to kinase inhibitor targeted therapies in lung cancers with specific genetic abnormalities (EGFR mutations, ALK translocations, KRAS mutations). Specifically, he is interested in discovering targetable mechanisms that promote tumor evolution and acquired drug resistance. Aaron earned his MD and PhD from Vanderbilt University School of Medicine, conducted his internship and residency in Internal Medicine at Brigham and Women’s Hospital, and completed Medical Oncology fellowship training at Dana Farber Cancer Institute and Massachusetts General Hospital.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Nuvalent
1 followers
Nuvalent is creating precisely targeted therapies for patients with cancer designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in structure-based design, Nuvalent develops innovative small molecules with exquisite target selectivity to overcome resistance, minimize adverse events, and drive more durable responses.